Designing viral vector clearance studies for CGT products according to ICH Q5A (R2): part 1

Watch the video or view the poster to learn more about: Starting material considerations for gene therapy products Limitations of traditional viral clearance processes  How to determine the appropriate log reduction factor for your product Case studies provided in ICH Q5A (R2)

Please enter your email to access content Read now